Successful Treatment with Crizotinib in Mechanically Ventilated Patients with ALK Positive Non–Small-Cell Lung Cancer Hee Kyung Ahn, MD, Kyeongman Jeon,

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer Haa-Na Song, MD,

Neoplastic Fever Caused by Lung Cancer

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

The Signature from Messenger RNA Expression Profiling Can Predict Lymph Node Metastasis with High Accuracy for Non-small Cell Lung Cancer Naeyun Choi,

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

ALK FISH and IHC: You Cannot Have One without the Other

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer Haa-Na Song, MD,

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.

Incidence of Brain Metastasis at the Initial Diagnosis of Lung Squamous Cell Carcinoma on the Basis of Stage, Excluding Brain Metastasis Hyun Lee, MD,

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer Maruja E. Lira, Tae Min Kim, Donghui Huang, Shibing Deng,

Electronic Updates for JTO Readers

Primary Pulmonary Choriocarcinoma Presenting with a Hemothorax

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib Sai-Hong Ignatius Ou, MD, PhD,

Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer: A Multicenter Trial by the Korean Cancer Study Group Ji Eun Uhm, MD, MSc, Byeong-Bae.

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors Hsin-Yi Wang, MD Journal of Thoracic.

Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors Su Jin Lee, MD, Jung-Il Lee,

Complete Radiological Response of Metastatic Anaplastic Lymphoma Kinase-Positive Signet Ring Lung Adenocarcinoma to Systemic Chemotherapy Grzegorz Korpanty,

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Neoplastic Fever Caused by Lung Cancer

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer Jeong-Ok Lee, MD, Tae Min.

High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Yang Zhang, MD, Haiquan Chen, MD, PhD

Atypical Thymoma (World Health Organization Type B3) with Neuroendocrine Differentiation Combined with Hyperparathyroidism Hyun Sik Park, MD, Sang Wha.

Outcomes of Mediastinoscopy and Surgery with or without Neoadjuvant Therapy in Patients with Non-small Cell Lung Cancer Who are N2 Negative on Positron.

Arnaud Uguen, MD, PhD Journal of Thoracic Oncology

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant.

Analysis of Tumor Markers in the Cytological Fluid Obtained from Computed Tomography-Guided Needle Aspiration Biopsy for the Diagnosis of Non-small Cell.

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for.

Daniel B. Costa, MD, PhD, Susumu Kobayashi, MD, PhD

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43– 9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern.

A Simple Solution for Complicated Pleural Effusions

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non–Small-Cell Lung Cancer Sang-Won Um, MD, PhD, Hong Kwan Kim, MD,

Impact of Chronic Obstructive Pulmonary Disease on the Mortality of Patients with Non– Small-Cell Lung Cancer Seung Jun Lee, MD, Jinwoo Lee, MD, Young.

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer Yoon Hee Choi, MD,

Analysis of Treatment Outcomes of Intraventricular Chemotherapy in 105 Patients for Leptomeningeal Carcinomatosis from Non–Small-Cell Lung Cancer Ho-Shin.

Ethnic Differences in the Management of Lung Cancer in New Zealand

Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer Eun Young Kim, MD, Young Saing Kim, MD, Inkeun Park, MD,

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

Validity of International Association for the Study of Lung Cancer Proposals for the Revision of N Descriptors in Lung Cancer Jin Gu Lee, MD, Chang Young.

Journal of Thoracic Oncology

P Post-Recurrence Survival Analysis of Stage I Non-Small Cell Lung Cancer: Prognostic Significance of Local Treatment Kanghoon Lee, Hyeong Ryul.

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

David Garfield, MD Journal of Thoracic Oncology

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC- Positive and FISH-Negative ALK Jong-Mu Sun, MD, PhD, Yoon-La Choi,

Gefitinib-Associated Propionibacterium acnes Pleural Empyema

A Review of First-Line Treatment for Small-cell Lung Cancer

Presentation transcript:

Successful Treatment with Crizotinib in Mechanically Ventilated Patients with ALK Positive Non–Small-Cell Lung Cancer Hee Kyung Ahn, MD, Kyeongman Jeon, MD, PhD, Hongseok Yoo, MD, Boram Han, MD, Su Jin Lee, MD, Hyeyon Park, MD, Min Ji Lee, MD, Sang Yun Ha, MD, Joung Ho Han, MD, PhD, Jong-Mu Sun, MD, PhD, Jin Seok Ahn, MD, PhD, Myung-Ju Ahn, MD, PhD, Keunchil Park, MD, PhD Journal of Thoracic Oncology Volume 8, Issue 2, Pages 250-253 (February 2013) DOI: 10.1097/JTO.0b013e3182746772 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Chest radiographs before and after crizotinib treatment in case 1. Journal of Thoracic Oncology 2013 8, 250-253DOI: (10.1097/JTO.0b013e3182746772) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Positive immunohistochemical staining for anaplastic lymphoma kinasein the cytoplasm of lung cancer cells (NCL-ALK [clone 5A4], Novocastra, United Kingdom). Journal of Thoracic Oncology 2013 8, 250-253DOI: (10.1097/JTO.0b013e3182746772) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Chest radiographs before and after crizotinib treatment in case 2. Journal of Thoracic Oncology 2013 8, 250-253DOI: (10.1097/JTO.0b013e3182746772) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Response to crizotinib in case 3. A chest wall metastatic mass and malignant pleural effusion on the right side reduced after 1 month of treatment. Journal of Thoracic Oncology 2013 8, 250-253DOI: (10.1097/JTO.0b013e3182746772) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions